ProQR to Present at Two Upcoming Investor Conferences in May

LEIDEN, the Netherlands, April 29, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), today announced that Daniel de Boer, Chief Executive Officer, will take part in a fireside chat at the Deutsche Bank 40th Annual Health Care Conference on Thursday, May 7, 2015 at 2:50pm ET and will give a presentation about the company's CF program at the Cystic Fibrosis Workshop hosted by JMP Securities on Friday May 8, 2015 at 11:00am ET. Both conferences will be in Boston, MA, USA.

The live and archived webcast of the fireside chat at the Deutsche Bank Conference will be accessible from the "Investor Relations" section of ProQR's website (www.proqr.com). The archived webcast will be available for 30 days following the presentation date.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe diseases such as cystic fibrosis and Leber's congenital amaurosis. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. Since 2012.

ProQR Therapeutics N.V.:
Smital Shah
Chief Financial Officer
T: +1 415 231 6431
ir@proqr.com

Media inquiries:
Gretchen Schweitzer
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +49 89 2424 3494
gschweitzer@macbiocom.com

You might like this

  • About ProQR Therapeutics

    ProQR was founded by Daniel de Boer with a mission to help people living with rare genetic diseases. This remains the main focus of our company today.

    Daniel de Boer wearing a blue suit stands with arm crossed in a laboratory setting.

  • Axiomer technology - RNA base editing

    A new way to use RNA oligonucleotides to alter RNA, discovered by ProQR. The Axiomer® technology enables the editing of specific single nucleotides in RNA using the cells own editing machinery.

    Axiomer RNA editing platform technology

  • Our science

    Our passion lies in discovering the latest RNA technologies and translating them to life-changing treatments for people with severe rare and common diseases.

    ProQR scientist working in the lab